Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trophos Blueprints Path To Exit With Actelion Option Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Trophos' deal with Actelion provides validation for the biotech's approach to rare disease R&D and lines up a solid exit for Trophos' venture backers - if Phase III data lives up to expectations.
Advertisement

Related Content

Actelion Passes On Trophos Acquisition After Failed Lou Gehrig's Study
Actelion Hedge-Fund Shareholder Urges Sale
Actelion Hedge-Fund Shareholder Urges Sale
Actelion, GSK Scrap Sleep Drug Almorexant
Actelion, GSK Scrap Sleep Drug Almorexant
Biotech Backers Are Learning to Live with Exit-by-Earn-out

Topics

Advertisement
UsernamePublicRestriction

Register

PS070935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel